End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.75 CNY | +0.04% | +0.22% | -9.11% |
Apr. 18 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
Apr. 17 | Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.11% | 7.49B | |
+27.92% | 659B | |
+27.68% | 557B | |
-4.59% | 359B | |
+16.38% | 322B | |
+9.39% | 297B | |
+6.30% | 215B | |
+4.80% | 210B | |
-6.05% | 200B | |
-8.58% | 149B |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Shanghai Fosun Pharmaceutical : Fosun Cancer Drug Approved for Clinical Trial